A guidance for renal biomarker lead optimization and use in translational pharmacodynamics

• Published in: Drug discovery today Vol. 15; no. 3; pp. 142 - 147
• Main Author: Ozer, Josef S.
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Ltd 01.02.2010; Elsevier
• Subjects: Albumins - metabolism; Animals; Associated diseases and complications; Autoimmune Diseases - metabolism; Bile Acids and Salts - metabolism; Biological and medical sciences; Biomarkers, Pharmacological - metabolism; Cathepsin B - urine; Cyclosporine - adverse effects; Cystatin C - blood; Cysteine - metabolism; Diabetes Mellitus, Type 2 - diagnosis; Diabetes Mellitus, Type 2 - urine; Diabetes. Impaired glucose tolerance; Drug Approval; Drug Evaluation, Preclinical - methods; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; General pharmacology; Humans; Immunosuppressive Agents - adverse effects; Kidney - blood supply; Kidney - drug effects; Kidney - metabolism; Leukotrienes - metabolism; Medical sciences; Models, Animal; Pharmaceutical technology. Pharmaceutical industry; Pharmacology. Drug treatments; Translational Medical Research - methods; Endocrinopathy; Kidney disease; Performance evaluation; Urinary system disease; Pharmaceutical technology; Diabetes mellitus; Biological marker; Biological activity; Optimization; Kidney; Concomitant disease; Nephropathy; Diabetic nephropathy; Diagnosis; Technique
• ISSN: 1359-6446; 1878-5832
• DOI: 10.1016/j.drudis.2009.12.001

Guidance for the use of biomarkers in pharmaceutical development and clinical trial optimization will reduce developmental cycle time. A ‘fit-for-purpose’ guidance for biomarker use is considered herein when the same biomarker is applied in very different contexts in drug development and after regulatory approval. Recent approved use of renal safety biomarkers in Good Laboratory Practice studies lacks sufficient guidance for the use of these markers across the drug development pipeline. In lead optimization, renal injury biomarkers are possible anchors for promising new prodromal metabolic biomarkers, which are applied before lead candidate selection. Renal injury biomarkers can now be evaluated as potential efficacy and pharmacodynamic biomarkers in clinical trial proof-of-concept studies for diabetic nephropathy.